UK Continuous Glucose Monitoring Market Size, Share, Opportunities, And Trends By Gender (Male, Female), By Age (Greater Than 20, Less Than 20), By Type (Real-Time CGM, Intermittent CGM), By Application (Diabetes Patients, Critical Care Patients), and By End-Users (Hospitals And Clinics, Homecare, Diagnostic Centers & Clinics), Forecasts From 2025 To 2030
- Published : Apr 2025
- Report Code : KSI061614922
- Pages : 105
UK Continuous Glucose Monitoring Market Size:
The UK continuous glucose monitoring market, valued at $899.846 million in 2030 from $570.921 million in 2025, is projected to grow at a CAGR of 9.53%.
The medical device known as continuous glucose monitoring (CGM) provides ongoing blood sugar observation services to both type 1 and type 2 diabetes patients through wearable apparatus design. A substantial rise in CGM market demand exists across the UK due to numerous market factors.
The increasing number of diabetes patients and enhanced public understanding of CGM devices benefit the market due to government policies and financial support. The market continues to rise because of growing disposable income combined with healthcare having increased prominence in the industry. Other technological observation tools join the CGM device as essential elements that drive modern healthcare. These healthcare devices enable remote patients to use monitoring devices combined with wearable sensors through continuous glucose monitoring systems (CGMS).
________________________________________
UK Continuous Glucose Monitoring Market Overview & Scope:
The UK continuous glucose monitoring market is segmented by:
- Gender: The male demographic in the market maintains the greatest share because men develop diabetes at higher rates than women. The growing rates of UK men developing prediabetes alongside obesity have boosted the widespread use of preventive CGM systems. The UK men's CGM market will expand at a noteworthy compound annual growth rate fueled by technological improvements and expanding insurance coverage together with positive healthcare management practices.
- Age: People who surpass the age of twenty show higher tendencies toward diabetes development. The NHS data shows that diabetes prevalence rates increased progressively with age throughout 2021 because adults below thirty-five had a 1% prevalence while adults seventy-five and above showed a 16% prevalence. The real-time glucose measurements provided by CGM systems minimize the risk of complications when blood sugar remains uncontrolled by documenting cardiovascular conditions and neuropathy. The increasing awareness of diabetes treatment methods leads to increased implementation of CGM devices.
- Type: By type, the UK continuous glucose monitoring market is segmented into real-time CGM and intermittent CGM.
- Application: The UK continuous glucose monitoring market consists of two sub-segments including diabetic patients and critical care patients under the application category. International Diabetes Federation predicts that the number of diabetes patients between 20–79 years old will increase from 3,996.3 (one thousand) in 2021 to 4,140.6 (one thousand) in 2030 and 4,408.1 thousand by 2045.
- End-Users: Healthcare organizations are likely to show increasing acceptance of advanced glucose monitoring technologies because UK clinics and hospitals will have robust CGM market growth. This pattern is also bolstered by expanding diabetes prevalence and healthcare programs focusing on enhanced diabetes control.
________________________________________
Top Trends Shaping the UK Continuous Glucose Monitoring Market
1. Increasing adoption and awareness
- There is increasing adoption of CGM devices by people with diabetes in the UK, led by increased awareness of their advantage in controlling blood glucose levels better. The National Health Service (NHS) has been at the forefront by making the devices more widely available, especially to people with type 1 diabetes, usually at the same cost as flash glucose monitors.
2. Technological advancements and innovation
Ongoing innovation in CGM technology is a key driver. This involves the creation of more precise sensors with extended wear periods (up to 14 days for a few), compact and unobtrusive wearable products, and connection with smartphones and other digital health systems through Bluetooth. Manufacturers are also concentrating on non-invasive or barely invasive solutions to the older electrochemical-based sensors.
________________________________________
UK Continuous Glucose Monitoring Market Growth Drivers vs. Challenges
Drivers:
- Rising prevalence of diabetes: The United Kingdom demands CGM devices to improve glucose control because of the increasing prevalence of diabetes in the nation. Healthcare costs associated with diabetes in the United Kingdom will rise progressively during the upcoming decades. For the year 2021, the total expenses reached USD 23,415.4 million. The market projection shows an expected growth of USD 23,815.4 million for 2030 with an estimated figure of USD 23,949.2 million as the industry forecast for 2045. Public health initiatives must strengthen diabetes prevention and management strategies because health costs will continue to increase as diabetes rates keep rising.
- Focus on Preventative Health: CGM market growth stems from its use by non-diabetic people who aim to maintain excellent health through a better understanding of body metabolism during food consumption and exercise.
Challenges:
- High Costs: NHS coverage expansion does not resolve the financial burden of CGM device costs including sensors, transmitters, and receivers. This high cost associated with CGM therefore negatively impacts the market.
________________________________________
UK Continuous Glucose Monitoring Market Competitive Landscape
The market is fragmented, with many notable players including Dexcom, Inc., Abbott Laboratories, and Medtronic plc among others:
- Expansion: In June 2024, Insulet Corporation announced the full availability of its Omnipod 5 Automated Insulin Delivery System in the United Kingdom and the Netherlands. Designed for individuals aged two years and older with type 1 diabetes, Omnipod 5 is compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus CGMs. It is the first and only tubeless automated insulin delivery (AID) system integrated with both leading CGM sensor brands, offering users greater flexibility and convenience in managing their diabetes.
________________________________________
Why Purchase This Report?
- 70+ pages of actionable data: Pricing trends, units, regional demands, analysis (2023-2030), and competitive benchmarking.
- Proprietary insights: Surveys from industry leaders.
- Excel deliverables: Pre-formatted tables for seamless integration into business strategies.
UK Continuous Glucose Monitoring Market Scope:
| Report Metric | Details |
| UK Continuous Glucose Monitoring (CGM) Market Size in 2025 | US$570.921 million |
| UK Continuous Glucose Monitoring (CGM) Market Size in 2030 | US$899.846 million |
| Growth Rate | CAGR of 9.53% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Million |
| Segmentation |
|
| List of Major Companies in the UK Continuous Glucose Monitoring (CGM) Market |
|
| Customization Scope | Free report customization with purchase |
UK Continuous Glucose Monitoring Market Segmentation:
By Gender
- Male
- Female
By Age
- Greater than 20
- Less than 20
By Type
- Real-time CGM
- Intermittent CGM
By Application
- Diabetes Patients
- Critical Care Patients
By End-Users
- Hospitals and Clinics
- Homecare
- Diagnostic Centers & Clinics
Our Best-Performing Industry Reports:
- Blood Glucose Monitoring Devices Market
- Portable Glucose Monitor Market
- Blood Glucose Test Strips Market
Frequently Asked Questions (FAQs)
The UK continuous glucose monitoring (CGM) market is expected to reach a total market size of US$899.846 million by 2030.
UK Continuous Glucose Monitoring (CGM) Market is valued at US$570.921 million in 2025.
The UK continuous glucose monitoring (CGM) market is expected to grow at a CAGR of 9.53% during the forecast period.
Rising diabetes cases, tech advances, aging population, and NHS support are key factors driving UK CGM market growth.
The UK Continuous Glucose Monitoring (CGM) Market has been segmented by Gender, Age, Type, Application, and End-Users.
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. UK CONTINUOUS GLUCOSE MONITORING MARKET BY GENDER
4.1. Introduction
4.2. Male
4.3. Female
5. UK CONTINUOUS GLUCOSE MONITORING MARKET BY AGE
5.1. Introduction
5.2. Greater than 20
5.3. Less than 20
6. UK CONTINUOUS GLUCOSE MONITORING MARKET BY TYPE
6.1. Introduction
6.2. Real-time CGM
6.3. Intermittent CGM
7. UK CONTINUOUS GLUCOSE MONITORING MARKET BY APPLICATION
7.1. Introduction
7.2. Diabetes Patients
7.3. Critical Care Patients
8. UK CONTINUOUS GLUCOSE MONITORING MARKET BY END-USERS
8.1. Introduction
8.2. Hospitals and Clinics
8.3. Homecare
8.4. Diagnostic Centers & Clinics
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Dexcom, Inc.
10.2. Abbott Laboratories
10.3. Medtronic plc
10.4. Roche Diabetes Care, Inc.
10.5. Senseonics Holdings, Inc.
10.6. Ascensia Diabetes Care Holdings AG
10.7. Insulet Corporation
10.8. Tandem Diabetes Care, Inc.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
Dexcom, Inc.
Abbott Laboratories
Medtronic plc
Roche Diabetes Care, Inc.
Senseonics Holdings, Inc.
Ascensia Diabetes Care Holdings AG
Insulet Corporation
Tandem Diabetes Care, Inc.
